J M Minor
Overview
Explore the profile of J M Minor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinot-Peignoux M, Comanor L, Minor J, Ripault M, Pham B, Boyer N, et al.
J Viral Hepat
. 2006 Sep;
13(10):701-7.
PMID: 16970602
Current models used to predict response to peginterferon plus ribavirin treatment, based on viral decline during the first 12 weeks of therapy, have focused on creating an early stopping rule...
2.
Krajden M, Minor J, Zhao J, Rifkin O, Comanor L
J Clin Virol
. 1999 Dec;
14(2):137-43.
PMID: 10588456
Objectives: Quantification of hepatitis C virus (HCV) RNA in serum is used to assess the probability of treatment response and to monitor antiviral therapy. Since serum specimens often are shipped...
3.
Krajden M, Minor J, Rifkin O, Comanor L
J Clin Microbiol
. 1999 May;
37(6):1683-6.
PMID: 10325307
Quantification of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA often is performed in specimens that have been frozen and thawed more than once. To ensure optimal...
4.
Lau D, Comanor L, Minor J, Everhart J, Wuestehube L, Hoofnagle J
J Viral Hepat
. 1998 May;
5(2):105-14.
PMID: 9572035
Therapy with interferon-alpha has been reported to induce remissions in 35% of patients with chronic hepatitis B. The ability to identify patients likely to respond would be helpful in making...
5.
Krajden M, Comanor L, Rifkin O, Grigoriew A, Minor J, Kapke G
J Clin Microbiol
. 1998 Feb;
36(2):382-6.
PMID: 9466745
Quantification of hepatitis B virus (HBV) DNA in serum is used to establish eligibility for treatment and to monitor therapeutic response. With the trend toward centralized testing, defining the conditions...
6.
Minor J, Namini H, Watson G
J Biopharm Stat
. 1996 Mar;
6(1):105-14.
PMID: 8838782
Given a set of measurements on a patient in clinical studies or on a drug response in bioassays and immunoassays, the data series for the individual can be incomplete, noisy,...
7.
Minor J, Namini H
J Biopharm Stat
. 1996 Mar;
6(1):83-104.
PMID: 8838781
Clinical studies investigate the interdependence of dosing regimen, efficacy, and side effects. These relationships often involve complex dynamical functions. The study of phenomena intermediate between dosing and efficacy, e.g., pharmacokinetics...